Progranulin (GRN) and TBK1 in Frontotemporal Degeneration

Progranulin (GRN) on human chromosome 17q21.31 and TANK-binding kinase 1 (TBK1) on human chromosome 12q14.2 are two major autosomal dominant haploinsufficiency genes responsible for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP, primarily histopathologic Type A and Type B) and amyotrophic lateral sclerosis (ALS). Together with the C9orf72 hexanucleotide repeat expansion and MAPT mutations, heterozygous loss-of-function mutations in GRN (~5–10% of all FTD and ~20–25% of familial FTD) and TBK1 (~1–4% of ALS–FTD) define the core genetic architecture of frontotemporal dementia.

Remarkably, GRN is located on Chr17q21.31 only 1.7 Mb centromeric to MAPT, explaining a decades-long clinical genetics puzzle in which numerous chromosome 17-linked FTD kindreds lacked MAPT mutations and exhibited ubiquitin/TDP-43-positive rather than tau-positive brain pathology. In 2006, Baker, Mackenzie, Rademakers, and Cruts demonstrated that >70 distinct nonsense, frameshift, and splice-site mutations in GRN induce nonsense-mediated mRNA decay (NMD) of the mutant transcript, reducing circulating plasma and cerebrospinal fluid (CSF) progranulin levels by 50% to 70%. Mechanistically, GRN and TBK1 converge with C9orf72 and LRRK2/GBA1 on the endolysosomal–autophagic axis: GRN maintains lysosomal bis(monoacylglycero)phosphate (BMP) levels and activates cathepsin D and β-glucocerebrosidase (GCase), while TBK1 phosphorylates the selective autophagy Cargo receptors optineurin (OPTN) and sequestosome-1 (SQSTM1/p62) to clear damaged mitochondria (mitophagy) and aggregated TDP-43.

The 7.5-Repeat Cysteine-Rich Precursor and Cathepsin Processing

The human GRN gene (13 exons spanning 8 kb on Chr17q21.31) encodes a 593-amino-acid, 68.5-kDa polypeptide backbone that is heavily N-glycosylated at five conserved asparagine residues (Asn118, Asn236, Asn265, Asn368, Asn530) to yield a secreted ~88-kDa glycoprotein (PGRN). Structurally, full-length progranulin consists of a 17-residue N-terminal signal peptide followed by 7.5 tandem repeats of a 12-cysteine granulin module (paragranulin p [half-repeat] followed by full-length granulins G–F–B–A–C–D–E, separated by short protease-sensitive linker peptides). Each ~6-kDa granulin module (55–60 residues) folds into a compact, hyperstable stack of four β-hairpins clamped together by six intramolecular disulfide bridges (Cys1–Cys3, Cys2–Cys5, Cys4–Cys8, Cys6–Cys10, Cys7–Cys11, Cys9–Cys12).

To reach the lysosome, extracellular or trans-Golgi progranulin utilizes two parallel receptor pathways:

1. Sortilin (SORT1) Endocytic Clearance: The C-terminal carboxylate tail of progranulin (Gln591–Pro592–Leu593, specifically Leu593) binds with high affinity (K_d ≈ 5–15 nM) inside the 10-bladed β-propeller tunnel of the neuronal and microglial receptor sortilin (SORT1), which rapidly internalizes extracellular progranulin and delivers it to the lysosome.
2. Prosaposin (PSAP) Piggyback Pathway: Progranulin forms a 1:1 heterodimer with prosaposin (PSAP, the precursor of saposins A–D) via granulin modules D and E, co-trafficking to lysosomes via the mannose-6-phosphate receptor (M6PR) and LRP1.

Once inside the acidic lysosomal lumen (pH 4.5), cysteine proteases—principally cathepsin L (CTSL) and cathepsin B—cleave the flexible inter-domain linkers of the 88-kDa progranulin precursor while sparing the disulfide-locked cores, liberating the individual 6-kDa granulin peptides (granulins A–G), which are stable in the proteolytic lysosomal interior.

Dosage Sensitivity: Heterozygous FTLD-TDP vs. Homozygous CLN11

Human genetics reveals a striking gene-dosage continuum at GRN. While heterozygous GRN loss-of-function causes adult-onset FTLD-TDP Type A (characterized by neuronal cytoplasmic inclusions and lentiform intranuclear inclusions of hyperphosphorylated, C-terminally cleaved TDP-43 in frontotemporal cortex Layer II), homozygous biallelic GRN mutations cause Neuronal Ceroid Lipofuscinosis Type 11 (CLN11)—a juvenile-to-young-adult lysosomal storage disorder presenting with retinal dystrophy, generalized seizures, cerebellar ataxia, and intracellular accumulation of autofluorescent lipofuscin ("fingerprint" storage bodies).

Lipidomic studies explain this convergence: inside the lysosome, progranulin and cleaved granulins directly bind and stabilize bis(monoacylglycero)phosphate (BMP), the essential negatively charged inner-membrane phospholipid required for GBA1 (GCase) and acid sphingomyelinase (ASM) to degrade glycosphingolipids, while granulin E directly binds and stimulates the maturation and catalytic activity of cathepsin D (CTSD). In GRN-deficient microglia, loss of BMP and cathepsin activity triggers lipid droplet accumulation, massive upregulation of complement proteins C1qa/C3, and excessive microglial synaptic pruning of thalamocortical and frontal circuits.

TANK-binding kinase 1 (TBK1) (Chr12q14.2, 21 exons encoding a 729-amino-acid, 84-kDa homodimeric Ser/Thr kinase comprising an N-terminal kinase domain, a ubiquitin-like domain ULD, and two coiled-coil scaffold dimerization domains CCD1/CCD2) was identified in 2015 through exome-wide burden sequencing as a major cause of dominant ALS and FTD. TBK1 governs two neuroprotective checkpoints:

1. Selective Autophagy (Mitophagy and Aggrephagy): Using its C-terminal CCD2 domain to bind the autophagy receptor optineurin (OPTN), TBK1 phosphorylates OPTN at Ser177 (increasing its binding affinity for autophagosomal LC3B ~10-fold) and phosphorylates SQSTM1/p62 at Ser403 within its ubiquitin-associated (UBA) domain (enhancing polyubiquitinated cargo capture), while also phosphorylating SMCR8 within the C9orf72 complex.
2. Suppression of RIPK1-Driven Necroptosis: Under TNF-α inflammatory signaling, TBK1 phosphorylates receptor-interacting serine/threonine-protein kinase 1 (RIPK1) at Thr189 to inhibit RIPK1 activation. When TBK1 haploinsufficiency combines with aging-related reduction of TAK1 (MAP3K7) expression in the human brain, unrestrained RIPK1 kinase activity triggers microglial neuroinflammation and necroptotic motor/cortical neuron death.

How does blocking the sortilin receptor with latozinemab (AL001) cure progranulin deficiency if sortilin delivers progranulin to lysosomes?

Although sortilin (SORT1) mediates rapid receptor-mediated endocytosis of extracellular progranulin, in the human central nervous system sortilin acts predominantly as a sink that clears and degrades >60% of secreted extracellular progranulin, while the prosaposin (PSAP)–M6PR/LRP1 heterodimer pathway remains fully capable of delivering progranulin to neuronal and microglial lysosomes independently of sortilin. Consequently, blocking sortilin with the monoclonal antibody latozinemab (AL001) prevents sortilin-mediated clearance, raising extracellular and CSF progranulin levels 2- to 3-fold in heterozygous GRN mutation carriers and driving sufficient PGRN through the PSAP pathway to restore lysosomal BMP homeostasis.

Why were GRN mutations missed for nearly a decade in families with chromosome 17-linked frontotemporal dementia?

The GRN gene on Chr17q21.31 lies only 1.7 Mb away from MAPT within the same genetic linkage peak discovered for FTDP-17. After MAPT mutations were identified in 1998, investigators searched for occult regulatory mutations around MAPT in the remaining tau-negative Chr17q21 families until systematic resequencing of neighboring genes in 2006 revealed that heterozygous nonsense and frameshift mutations in GRN—whose mutant mRNAs were degraded by nonsense-mediated decay—accounted for all tau-negative Chr17q21 kindreds.

How does the TMEM106B genetic modifier alter disease penetrance in GRN mutation carriers?

TMEM106B (Chr7p21.3) encodes a 274-amino-acid late endosomal/lysosomal type II transmembrane glycoprotein whose luminal C-terminal domain (residues 120–254) is cleaved and assembles into amyloid filaments in aging brains. The common protective coding variant Ser185 (rs3173615, tagged by rs1990622-G) accelerates TMEM106B turnover, elevates plasma progranulin levels, and reduces the odds of developing clinical FTLD-TDP by ~50% in heterozygous GRN mutation carriers (homozygous Ser185/Ser185 GRN carriers frequently remain asymptomatic into late life).

1. Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., et al. (2006). "Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17." Nature, 442(7105), 916–919. https://doi.org/10.1038/nature05016
2. Cirulli, E. T., Lasseigne, B. N., Petrovski, S., et al. (2015). "Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways." Science, 347(6229), 1436–1441. https://doi.org/10.1126/science.aaa3650
3. Logan, T., Simon, M. J., Rana, A., et al. (2021). "Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic." Cell, 184(18), 4651–4668. https://doi.org/10.1016/j.cell.2021.07.029
4. Xu, D., Jin, T., Zhu, H., et al. (2018). "TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging." Cell, 174(6), 1477–1491. https://doi.org/10.1016/j.cell.2018.07.041